{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-177433","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.507147+00:00","generated_at":"2026-05-17T15:29:52.717373+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"First patient dosed in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome by Stoke and Biogen","bullets":["First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.","Randomized 1:1 vs sham over 52 weeks; primary endpoint: change in major motor seizure frequency at Week 28.","Zorevunersen is an investigational antisense oligonucleotide; potential first disease-modifying treatment for Dravet syndrome.","Key secondary endpoints include cognition/behavior via Vineland-3 subdomains at Week 52.","Enrollment: ages 2-18 with SCN1A mutation; open-label extension offered to eligible participants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-177433","json":"https://secwatch.observer/filing/0001193125-25-177433.json","markdown":"https://secwatch.observer/filing/0001193125-25-177433.md","text":"https://secwatch.observer/filing/0001193125-25-177433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525177433/0001193125-25-177433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000119312525177433/d64221d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:29:52.717373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}